# Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

> **NCT06725121** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 48 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Macrovascular Invasion
- Liver Transplant Surgery
- Downstaging

## Interventions

- **BIOLOGICAL:** Atezolizumab & Bevacizumab
- **DRUG:** Yttrium-90 (Y-90)
- **RADIATION:** Stereotactic body radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT06725121
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2031-06
- **Final completion:** 2034-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06725121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06725121, "Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06725121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*